https://www.selleckchem.com/pr....oducts/Semagacestat(
2±20.3 units vs 17.4±21.7 units, P=NS by Fisher's exact test), or positivity on this testing (11 of 169 [6.5%] positive vs 8 of 89 [8.9%], χ =0.53, P=.46, 95% CI 0.95-1.1). Neither renal disease nor hypothyroidism increased the risk of premature ovarian failure in these women receiving cyclophosphamide. Anti-ovarian antibodies among women with SLE are not associated with premature ovarian failure after treatment with cyclophosphamide. Anti-ovarian antibodies among women with SLE are not associated with premature ovarian f
Like
Comment
Share
